How are Investors Treating These Biotech? - Portola Pharma, Vitae Pharma, Anthera Pharma, and Intra-Cellular Therapies

May 19, 2016, 08:35 ET from Chelmsford Park SA

NEW YORK, May 19, 2016 /PRNewswire/ --

There is no saying when exactly the Biotech space will fully recover given the relentless pressures in pricing and lack in consumer confidence. One thing is for sure in the investors circle though - numerous opportunities are up for grabs but this industry requires due-diligence. Ahead of today's session,'s presents four names in this sector: Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Vitae Pharmaceuticals Inc. (NASDAQ: VTAE), Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), and Intra-Cellular Therapies Inc. (NASDAQ: ITCI). Receive your complimentary alerts on these stocks by signing up today at:

Below are these stocks' performances at the close on Wednesday, May 18, 2016:

Portola Pharmaceuticals Inc.'s shares surged 5.37% and finished the trading session at $25.91. A total volume of 763,111 shares was traded. In the last one month, the stock has advanced 7.11%. The Company's shares are trading above their 50-day moving average 5.49%. Moreover, shares of Portola Pharmaceuticals have a Relative Strength Index (RSI) of 56.20. Sign up and get the alert on PTLA at:

On Wednesday, shares in Vitae Pharmaceuticals Inc. recorded a trading volume of 202,910 shares, and ended the session 3.92% higher at $7.69. The stock has gained 1.99% in the last one month. The Company's shares are trading 14.24% above their 50-day moving average. Furthermore, Vitae Pharmaceuticals' stock has an RSI of 57.64. The complimentary alert on VTAE can be activated at:

Shares in Anthera Pharmaceuticals Inc. closed the day at $3.36, which was a correction of 1.18%. The stock recorded a trading volume of 410,156 shares. The Company's shares have surged 15.86% in the previous three months and are trading 9.67% below their 50-day moving average. Additionally, Anthera Pharmaceuticals' stock has an RSI of 45.92. Register for free on and access the latest strategies on ANTH at:

At the closing bell yesterday, shares in Intra-Cellular Therapies Inc. ended 2.61% higher at $34.59, and with a total volume of 355,491 shares traded. The stock has advanced 15.88% in the previous three months. The Company's shares are trading above their 50-day moving average by 9.73%. Furthermore, shares of Intra-Cellular Therapies have an RSI of 56.15. The complete trade setup on ITCI is available for free at:


Active Wall Street: 

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

AWS has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly at: Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom Email: Phone number:  1-858-257-3144

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA